DC Chemicals

DC67292 · Updated 28 October 2026

IAJD34

Literature evidence · DC67292

Formulation & Performance

The study uses IAJD34 as the sole amphiphilic carrier. Reporter expression, TGF-β pharmacology and lung-injury outcomes are separate experiments and are presented with their own doses and observation windows.

IAJD34 is not a conventional four-component lipid mixture. DSPC, cholesterol and PEG-lipid are not components of the cited one-component formulation.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
IAJD34DC672921392.911001.392910

IAJD34 is 100% of the carrier amphiphile; RNA is listed separately. The reported IAJD34:mRNA mass ratio is 40:1. Assembly used 10 mM acetate at pH 4.0. N/P was not established in this review and is not inferred from the mass ratio.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
IAJD34——

Carrier properties and stability

Study / conditionResultInterpretation
IonizationReported IAJD34 pKa 6.74Lung-targeted carrier selected for the study.
Luciferase formulation storageReporter potency retained after 5 days at 4°CBiological potency assessment for that cargo and interval.
TGF-β formulation storageParticle size and PDI followed over 5 weeks at 4°CPhysical stability does not establish 5-week biological potency.

Main Fig. 1, Supplementary Fig. 2 and Methods. No batch particle-size specification is inferred.

Luciferase mRNA delivery and time course

Study / conditionResultInterpretation
BALB/c mice; 10 µg mRNA; intravenousPredominantly pulmonary expression on organ imaging at 4 hWhole-body and isolated-organ measurements are distinct.
Whole-body flux at 4 h3.12 × 10^7 ± 9.15 × 10^6 photons/sThis reported value is not lung-only flux.
Serial imagingExpression declined at 24, 48 and 72 hTransient expression; no permanent transfection claim.
Dose exploration10, 20 and 30 µg mRNA evaluatedDifferent time points and doses must not be compared as a single potency metric.

Main Fig. 1 and Supplementary Tables 2–3.

TGF-β expression and biological activity

Study / conditionResultInterpretation
10, 20 or 30 µg TGF-β mRNA; intravenous; 24 hIncreased mature/cleaved TGF-β in bronchoalveolar lavage (BAL)Cargo-specific protein production; not a universal carrier endpoint.
Total TGF-βIncreases were reported at 20 and 30 µgTotal and cleaved protein assays are distinct.
Spatial and time-course studiesPulmonary immunostaining and 4–48 h protein/cellular analysesSupports transient pulmonary pharmacology; see source plots for endpoint-specific groups.

Main Figs. 3–7; assay-specific sample sizes and statistical tests are provided in the linked captions.

Dose-dependent tolerability

Study / conditionResultInterpretation
Highest TGF-β mRNA dose: 30 µg; 24 hIncreased BAL protein and neutrophils; increased serum ALTEvidence of pulmonary barrier/inflammatory effects and a liver-enzyme signal.
Histological responseDose-related fibrin and inflammatory-cell changes in lungActivity of the TGF-β payload contributes to the observed response.
Other safety readoutsAST did not show the same increase; other examined organs lacked corresponding overt histological injuryThese observations do not support a blanket claim of no toxicity.

Main dose-response figures and supplementary safety analyses. Results apply to the tested formulation and payload.

Bleomycin lung-injury model: benefits and limits

Study / conditionResultInterpretation
BALB/c mice; 10 µg TGF-β mRNA delivered concurrently with injury inductionAssessed 3 days later against empty-carrier and PBS groupsAn early intervention/co-administration model, not reversal of established fibrosis.
Lung responseReduced selected inflammatory signals and recruited alveolar macrophage response; preservation of the large-aggregate surfactant poolReadouts describe specific components of injury.
Endpoints without rescueTreatment did not prevent injury-associated body-weight loss or resident alveolar macrophage depletionTherapeutic effects were partial and endpoint-dependent.

Main Figs. 8–10 and supplementary data; long-term fibrosis and clinical benefit were not established.

Original study figures

Lung delivery and expression — Figure 1 — Original source figures.

Lung-injury outcomes — Figures 8–10 — Original source figures.

References and source locations

  1. Meshanni JA et al. Targeted delivery of TGF-β mRNA to murine lung parenchyma using one-component ionizable amphiphilic Janus Dendrimers. Nature Communications 16, 1806 (2025). DOI: 10.1038/s41467-025-56448-y